Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.
Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA.
Liveringhouse CL, et al. Among authors: caudell jj.
Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):837-848. doi: 10.1016/j.ijrobp.2023.01.006. Epub 2023 Jan 17.
Int J Radiat Oncol Biol Phys. 2023.
PMID: 36657497
Clinical Trial.